SBRT With Atezo/Bev for HCC

Description

A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)

Conditions

Hepatocellular Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)

A Phase I Study of SBRT Vaccination With Atezolizumab and Bevacizumab for Patients With Advanced Hepatocellular Carcinoma

SBRT With Atezo/Bev for HCC

Condition
Hepatocellular Carcinoma
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104-4283

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subjects must have hepatocellular carcinoma (HCC) that is not amenable to curative-intent surgical or ablation (where surgery or ablation are not indicated due to disease extent, co-morbidities, or other technical reasons) and systemic therapy is indicated.

Ages Eligible for Study

18 Years to 99 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Abramson Cancer Center at Penn Medicine,

Edgar Ben-Josef, MD, PRINCIPAL_INVESTIGATOR, Abramson Cancer Center

Study Record Dates

2026-12-31